Table 1.
Patient characteristics for the whole group (N = 35) and broken down by subsequent treatment, i. e. chemotherapy only or chemotherapy plus bevacizumab
| Variable | N total (%) | CHT (N = 25) N (%) |
CHT+BEV (N = 10) N (%) |
|---|---|---|---|
| Initial stage | |||
| IB | 4 (11) | 3 (12) | 1 (10) |
| IIB | 18 (52) | 15 (60) | 3 (30) |
| IIIA–IIIB | 8 (22) | 4 (16) | 4 (40) |
| IVA | 3 (9) | 3 (12) | 0 |
| IVB | 2 (6) | 0 | 2 (20) |
| Histology | |||
| Squamous cell carcinoma | 27 (77) | 20 (80) | 7 (70) |
| Adenocarcinoma or adeno-squamous | 8 (23) | 5 (20) | 3 (30) |
| Grade | |||
| G1 | 3 (9) | 2 (8) | 1 (10) |
| G2 | 14 (40) | 9 (36) | 5 (50) |
| G3 | 13 (37) | 10 (40) | 3 (30) |
| Not evaluated | 5 (14) | 4 (16) | 1 (10) |
| Median age (years) | 51 (32–78) | 53 (32–78) | 49 (32–64) |
| ECOG | |||
| 0 | 21 (60) | 14 (56) | 7 (70) |
| 1 | 12 (34) | 10 (40) | 2 (20) |
| 2 | 2 (6) | 2 (4) | 1 (10) |
| Comorbidities | |||
| Diabetes | |||
| Yes | 2 (6) | 1 (4) | 1 (10) |
| No | 33 (94) | 24 (96) | 9 (90) |
| Hypertension | |||
| Yes | 12 (34) | 7 (28) | 5 (50) |
| No | 23 (66) | 18 (72) | 5 (50) |
| GI surgery | |||
| Yes | 2 appendectomy, 3 bowel resection (14) | 4 (16) | 1 bowel resection (10) |
| No | 30 (86) | 21 (84) | 9 (90) |
| Thromboembolic event | |||
| Yes | 6 (17) | 2 (8) | 4 (40) |
| No | 29 (83) | 23 (92) | 6 (60) |
| Primary treatment | – | CHT | CHT+BEV |
| EBRT dose (Gy) | 45 | 45 | 45 |
| EBRT pelvis (n) | 20 | 15 | 5 |
| EBRT extended-field (n) | 15 | 10 | 5 |
| EBRT IMRT/VMAT (n) | 6 (17) | 0 | 6 (17) |
| EBRT 3D conformal (n) | 29 (83) | 29 (83) | 6 (17) |
| BT IC only (n) | 4 (14) | 4 (16) | 0 |
| BT IC/interstitial | 31 (86) | 21 (84) | 10 (100) |
| Surgical LN staging | |||
| Yes | 26 (74) | 20 (80) | 6 (60) |
| Response rate at initial treatment | |||
| Complete | 25 (71) | 18 (72) | 7 (70) |
| Partial | 10 (29) | 7 (28) | 3 (30) |
| Type of recurrence | |||
| Local/pelvic | 7 (20) | 5 (20) | 2 (20) |
| Distal | 20 (57) | 13 (52) | 7 (70) |
| Combination | 8 (23) | 7 (28) | 1 (10) |
| Pelvic minor intervention/surgery/biopsy after RecCC | |||
| Yes | 17 (49) | 12 (48) | 5 (50) |
| No | 18 (51) | 13 (52) | 5 (50) |
| Response rate (to treatment for recurrence) | |||
| Complete | 7 (20) | 5 (20) | 2 (20) |
| Partial | 5 (14.3) | 2 (8) | 3 (30) |
| Stable disease | 4 (11.4) | 3 (12) | 1 (10) |
| Progressive disease | 15 (42.9) | 11 (44) | 4 (40) |
| Unknown | 4 (11.4) | 4 (16) | 0 |
| Median follow-up from recurrence (months) | 11 (0–50) | 11 (0–50) | 11 (5–28) |
| Median follow-up from recurrence to event (months) | 8 (2–27) | 11 (2–20) | 8 (5–27) |
| Median follow-up from diagnosis (months) | 26 (5–87) | 22 (5–87) | 38 (15–48) |
| Alive with no evidence of disease | 5 (14.3) | 4 (16) | 1 (10) |
| Alive with stable disease | 7 (20.0) | 4 (16) | 3 (30) |
| Alive with progressive disease | 6 (17.1) | 4 (16) | 2 (20) |
| Died intercurrently | 1 (2.9) | 0 | 1 (10) |
| Died of cancer | 16 (45.7) | 13 (52) | 3 (30) |
CHT chemotherapy, BEV bevacizumab, ECOG Eastern Cooperative Oncology Group, GI gastrointestinal, EBRT external beam radiotherapy, IMRT intensity-modulated radiotherapy, VMAT volumetric-modulated arc therapy, LN lymph node, RecCC recurrent cervical cancer, BT IC intracavitary only brachytherapy